ArticleCureus2025
Dexmedetomidine in Spinal Anesthesia for Orthopedic Surgery: Extending Analgesia Beyond the Operating Room.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal anesthesia is widely used in total knee arthroplasty (TKA) because it provides reliable block characteristics and favorable perioperative outcomes. However, a key limitation is the relatively short duration of local anesthetics, which may require additional analgesia or a switch to general anesthesia. To address this, intrathecal adjuvants are used to extend the duration of the block and enhance postoperative pain management. Dexmedetomidine, a highly selective α₂-adrenergic agonist, has demonstrated sedative and analgesic properties without respiratory depression, making it an attractive alternative to opioids such as fentanyl. In this case series, 10 µg of intrathecal dexmedetomidine was combined with ropivacaine in 20 patients undergoing TKA. Outcomes assessed included onset and regression of sensory and motor block, postoperative pain scores, and hemodynamic stability. Dexmedetomidine produced a rapid block onset, extended sensory block lasting up to 12 hours in some patients, and a predictable pattern of motor regression. Postoperative analgesia was favorable, with most patients remaining pain-free for the first six hours and reporting only mild discomfort at 12 hours. Hemodynamic changes observed included reductions in heart rate (HR) and mean arterial pressure (MAP), with some patients requiring vasopressor support, though no serious adverse events occurred. Our findings align with randomized controlled trials (RCTs) and meta-analyses indicating that intrathecal dexmedetomidine extends block duration, reduces the need for postoperative analgesics, and offers a favorable efficacy and side-effect profile compared to fentanyl. This case series adds to the existing body of evidence by presenting real-world clinical data on the use of intrathecal dexmedetomidine as an adjuvant to ropivacaine in elderly patients undergoing TKA. It demonstrates the adjuvant's safety, hemodynamic stability, and analgesic effectiveness in a routine hospital setting, supporting the applicability of findings from controlled trials to everyday anesthetic practice. Further large-scale studies are needed to refine dosing strategies and evaluate long-term outcomes in orthopedic populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.